| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [2] |
Chen L, Li J, Wang Z, et al. A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor-positive, HER-2-negative breast cancer: FINEST study[J]. J Clin Oncol, 2023，41(16): 607-607.
|
| [3] |
Xu B, Hu X, Li W, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4[J]. Eur J Cancer, 2022，175：236-245.
|
| [4] |
Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER-2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021，27(11)：1904-1909.
|
| [5] |
Li J, Jiang Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification[J]. Cancer Biol Med，2022，19(6)：769-773.
|
| [6] |
Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER-2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2023，24(6)：646-657.
|
| [7] |
Xu B, Zhang Q, Luo Y, et al. LEONARDA-1: phase III randomized study of lerociclib plus fulvestrant in patients with HR+，HER-2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy[J]. J Clin Oncol, 2023，41(16): 1017.
|
| [8] |
Wang J, Zhang Q, Sun T, et al. A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER-2－ metastatic breast cancer[J]. J Clin Oncol, 2023，41(16)：1072.
|
| [9] |
Xu B, Zhang Q, Hu X, et al. A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer[J]. Cancer Res, 2022，82(4): GS1-06.
|
| [10] |
Li L, Chen M, Zheng S, et al. Clinical and genetic predictive models for the prediction of pathological complete response to optimize the effectiveness for trastuzumab based chemotherapy[J]. Front Oncol, 2021，11：592 393.
|
| [11] |
Niu N, Qiu F, Xu Q, et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer[J]. Nat Commun, 2022，13(1)：7043.
|
| [12] |
Hua X, Bi X, Zhao J, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002)[J]. Clin Cancer Res, 2022，28(4)：637-645.
|
| [13] |
Zhang J, Meng Y, Wang B, et al. PLEASURABLE: results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER-2+) metastatic breast cancer (MBC)[J]. J Clin Oncol, 2023，41(16): 1046-1046.
|
| [14] |
Squifflet P, Saad ED, Loibl S, et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy[J]. J Clin Oncol, 2023，41(16)：2988-2997.
|
| [15] |
Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial[J]. BMC Med, 2022，20(1)：498.
|
| [16] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2023[M]. 北京：人民卫生出版社，2023：29.
|
| [17] |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021，22(3)：351-360.
|
| [18] |
Xu B, Yan M, Ma F, et al. LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase III trial[J]. Ann Oncol, 2022，33: S1387.
|
| [19] |
Lee KS, Wang X, Im Y, et al. Zanidatamab (zani), a HER-2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER-2-positive breast cancer (BC): updated results from a phase 1b/2 study[J]. J Clin Oncol, 2023，41(16): 1044.
|
| [20] |
Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial[J]. Lancet Oncol, 2022，23(3)：353-361.
|
| [21] |
Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with HER-2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial[J]. J Clin Oncol, 2023，41(16): 1048.
|
| [22] |
Li Q, Cheng Y, Tong Z, et al. FS-1502 in HER2-positive advanced breast cancer: results from an open-label, phase 1 study[J]. J Clin Oncol, 2023，41(16): 3044.
|
| [23] |
Lv H, Yan M, Sun T, et al. Anti-HER-2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER-2-positive metastatic breast cancer: final results from the phase 2 ICU trial[J]. J Clin Oncol, 2023，41(16): 1042.
|
| [24] |
Yan M, Niu L, Lv H, et al. 276P dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER-2+ advanced breast cancer: interim results of a phase II trial[J]. Ann Oncol, 2021，32: S484.
|
| [25] |
Yan M, Niu L, Lv H, et al. Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01)[J]. J Clin Oncol, 2023, 41(16): 1045.
|
| [26] |
Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020，18(4)：452-478.
|
| [27] |
Yan W, Wu X, Wang S, et al. Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial[J]. Ther Adv Med Oncol, 2022，14：17588359221107111.
|
| [28] |
Wang C, Wang R, Zhang G, et al. Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: a single-center, randomized, controlled, phase-II clinical study[J]. J Clin Oncol, 2023，41(16): 593.
|
| [29] |
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020，382(9)：810-821.
|
| [30] |
Jiang Z, Yu Z, Geng C, et al. Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer[J]. J Clin Oncol, 2023，41(16)：602.
|
| [31] |
Lee KL, Kuo YC, Ho YS, Huang YH. Triple-negative breast cancer: current understanding and future therapeutic breakthrough targeting cancer stemness[J]. Cancers (Basel), 2019，11(9)：1334.
|
| [32] |
Wang B, Sun T, Zhao Y, et al. A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer[J]. Nat Commun, 2022，13(1)：4025.
|
| [33] |
Liu J, Wang Y, Tian Z, et al. Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer[J]. Nat Commun, 2022，13(1)：3011.
|
| [34] |
Jiang Z, Ouyang Q, Sun T, et al. TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)[J]. J Clin Oncol, 2023，41(17)：LBA1013.
|
| [35] |
Wang J, Sun T, Ouyang Q, et al. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer[J]. iScience, 2023，26(6)：106 876.
|
| [36] |
Li C, Shao Z, Wang Z, et al. The overall survival analysis of FUTURE-C-PLUS: combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—an open-label, single-arm, phase 2 trial[J]. J Clin Oncol, 2023，41(16): 1086.
|
| [37] |
Shao Z, Lei F, Ma L, et al. FUTURE-SUPER: a randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer. J Clin Oncol, 2023，41(16)：3011.
|